Disclosure Of Entity's Operating Segments [Text Block]

Medicover - Filing #690784

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Disclosure of entity's operating segments [text block]
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
1 510,2 EUR
1 377,4 EUR
Interest income
27,000,000 EUR
10,000,000 EUR
Interest expense
345,000,000 EUR
201,000,000 EUR
Tax expense (income)
58,000,000 EUR
372,000,000 EUR
Profit (loss) before tax
198,000,000 EUR
1,438,000,000 EUR
Profit (loss)
EUR
EUR
EUR
140,000,000 EUR
121,000,000 EUR
19,000,000 EUR
EUR
121,000,000 EUR
EUR
EUR
EUR
48,000,000 EUR
EUR
EUR
EUR
EUR
1,018,000,000 EUR
EUR
EUR
EUR
1,066,000,000 EUR
1,018,000,000 EUR
Assets
1 831,7 EUR
1 684,3 EUR
Liabilities
1 320,9 EUR
1 122,2 EUR
Cash flows from (used in) operating activities
1,702,000,000 EUR
2,167,000,000 EUR
Cash flows from (used in) investing activities
1,848,000,000 EUR
3,336,000,000 EUR
Cash flows from (used in) financing activities
243,000,000 EUR
1,641,000,000 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.